Peptide Deformylase Inhibitors - Blog

Overview

The sharp rise in S. pneumoniae resistance to penicillin, macrolides, and other antimicrobials is concerning. Although fluoroquinolones currently have relatively low levels of resistance in the community, experts expect resistance to this class to increase as use becomes more widespread, which could limit future antibacterial options.

As a result, there is significant interest in developing novel antimicrobials, including peptide deformylase inhibitors, that may be active against pathogens resistant to currently available agents. Peptide deformylase is an enzyme involved in bacterial protein synthesis, and this target is highly conserved across bacterial species. Therefore, peptide deformylase inhibitors may provide broad-spectrum activity. In addition, there appears to be minimal interaction with components of human protein synthesis; as a result, these inhibitors are likely to show favourable selectivity for bacteria (and therefore safety in humans).

Peptide deformylase inhibitors are at an early stage of development, but they have generated substantial interest because of the need for novel, innovative antibacterials. Further trial results will be needed to determine their efficacy and likely future role. Several companies, including Roche, are pursuing early-stage development of peptide deformylase inhibitors. Because clinical trial information is limited, Roche's compounds are not discussed in detail.

Overall, this class represents a strategy that targets highly conserved bacterial pathways while aiming to spare human protein synthesis, which may translate into useful options if resistance to current drugs continues to increase.

Table 1. Key features of peptide deformylase inhibitors
Aspect	Key details	Potential clinical implication
Primary target	Peptide deformylase enzyme involved in bacterial protein synthesis	Provides a novel mechanism distinct from penicillins, macrolides, and fluoroquinolones.
Conservation of target	Highly conserved across bacterial species	Potential for broad-spectrum antibacterial activity.
Selectivity for bacteria	Minimal interaction with components of human protein synthesis	May offer favourable safety and tolerability in humans.
Development stage	Early-stage development with limited clinical trial data	Future studies are required to define their role in therapy.
Clinical need	Rising resistance in S. pneumoniae to multiple standard classes	Drives investigation of new agents for community-acquired respiratory tract infections.

Mechanism of Action

Peptide deformylase is an essential bacterial metalloenzyme required for protein synthesis and therefore represents a promising target for antibacterial therapy. Peptide deformylase inhibitors act on the peptide deformylase enzyme, disrupting protein maturation and inhibiting protein synthesis. Under normal conditions, bacterial protein synthesis is initiated by the amino acid formyl-methionyl-tRNA. Consequently, all nascent polypeptides are synthesized with N-formyl-methionine at the N terminus. Peptide deformylase removes the formyl group during elongation of the polypeptide chain. Deformylation is also a prerequisite for protein maturation. Peptide deformylase inhibitors act on peptide deformylase to prevent deformylation of the growing peptide chain and thereby inhibit protein synthesis.

By interfering at this early step in protein maturation, these agents may exert rapid bacteriostatic or bactericidal effects, depending on the organism and exposure, while leaving human protein synthesis largely unaffected.

BB-81384

Oscient Pharmaceuticals (formerly Genesoft/Genome Therapeutics), under licence from Vernalis (formerly British Biotech), was developing a lead compound from a series of IV peptide deformylase inhibitors for the potential treatment of bacterial infections, and respiratory tract infections (RTIs) in particular. The agent was being explored as an IV therapy for potential use in acute exacerbations of chronic bronchitis. However, in March 2004, Genome Therapeutics stated that this first-generation compound did not have the ideal spectrum of activity against common respiratory pathogens and that the company was exploring second-generation, orally available peptide deformylase inhibitors with greater potential to address the broader antibiotic market. Oscient Pharmaceuticals is currently investigating several preclinical oral peptide deformylase inhibitors for community-based RTIs. Several compounds have been identified as having attractive antibacterial properties, including good activity against H. influenzae.

BB-81384 is a novel peptide deformylase inhibitor with good in vitro activity against S. pneumoniae. It is the first compound in this class to be profiled for oral pharmacokinetics, and it has demonstrated oral antipneumococcal efficacy in mice. Pharmacokinetic studies in mice showed that the agent has good oral bioavailability. BB-81384 was a potent and selective inhibitor of peptide deformylase, with an IC50 of approximately 10 nM against most S. pneumoniae pathogens. In lung and thigh infection models, BB-81384 reduced the bacterial load.

These findings suggest that BB-81384 can reach effective concentrations at sites of respiratory infection in animal models; however, its eventual clinical usefulness will depend on human pharmacokinetics, safety, and comparative efficacy.

Table 2. Properties of BB-81384 described in preclinical studies
Property	Key data	Potential relevance
Class	Peptide deformylase inhibitor	Represents a first-in-class approach targeting protein maturation.
In vitro activity	Good activity against S. pneumoniae	Supports development for respiratory tract infections.
IC50 values	Approximately 10 nM against most S. pneumoniae pathogens	Indicates potent inhibition of the enzyme target in laboratory assays.
Oral pharmacokinetics	First compound of this class profiled for oral pharmacokinetics	Provides early evidence for possible oral dosing in humans.
Bioavailability	Good oral bioavailability in mice	Suggests that effective systemic levels may be achievable with oral therapy.
In vivo efficacy	Reduced bacterial load in lung and thigh infection models	Demonstrates proof of concept for activity in experimental infections.